LOXL4 and hepatocellular carcinoma: In contrast, other study revealed that 5-azacytidine (5-aza-CR)-mediated overexpression of LOXL4 reactivated wild-type p53 and promoted cancer cell death, thus suppressing the development of HCC cancers, which might indicate an improved clinical outcomes of HCC patients (28, 44).